ACIU
AC Immune SA
NASDAQ · Healthcare · Biotechnology · CH
$2.20
+5.26%Year over year
Reported trailing growth
- Revenue
- -39.5%
- EBITDA
- +13.2%
- EBIT
- +11.9%
- EPS
- +10.2%
- Free cash flow
- +19.9%
- Operating cash flow
- +18.4%
Forward estimates
Based on analyst estimates
- Revenue
- -88.8%
- EBITDA
- +69.0%
- EPS
- +67.8%
Three-year CAGR
- Revenue
- -3.2%
- EBITDA
- -39.4%
- EBIT
- -31.5%
- Net income
- -38.4%
- EPS
- -37.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026